Ideas
01Introduction

What makes a clinical trial resilient?

Building resilient clinical trials

By David Tsai

Read the article

I’ve spent the last 15 years in clinical research and drug development, with the first several years working at a large academic hospital enrolling patients onto clinical trials.

More about me

The way we run them has not changed much since.

Every medicine in your cabinet exists because people you have never met agreed to take part in a clinical trial.

Other people you have never met ran those trials.

All of them contributed to the medicines that treat and cure us today.

Select a role to see what it means.

Humans are resilient. It is the most basic thing about us.

In February of this year, I stood in front of a room of people who run clinical trials for a living and asked them 3 questions, one at a time, by a show of hands.

“How many of you have run a clinical trial?”

Nearly every hand in the room went up.

“How many of you have been in a clinical trial?”

Most of those hands came down.

“How many of you would participate in a trial you’ve run?”

A few were left.

Part of that distance comes from the pace of the world around trials, and it is speeding up.

Steam took a century to become infrastructure.

Electricity took 80 years.

Computers took about 40.

The internet took about 20.

AI has had 5.

Trials have to keep up with that pace using the people, sites and systems they run on today.

Steam engine1700s–1800s
100 yrs
Electricity1800s–1900s
80 yrs
Computers1950s–1990s
40 yrs
Internet1990s–2010s
20 yrs
AI2020–
5 yrs
020406080100
Years to become infrastructure

Instagram took 2.5 years to reach 100 million users.

ChatGPT took about 2 months.

Instagram took 2.5 years to reach 100 million users.ChatGPT took about 2 months.

0230 28 months sooner

Each dot is 10,000 users

Source: UBS estimate reported by Reuters, February 2023

Today, trial technology is built either by technology companies or by trial experts.

There are 2 familiar answers, and neither is enough on its own.

Technology-led. Explosive launch, rapid adoption, and then the technology does not fit how trials actually run. Adoption craters and trust goes with it.

Expert-led. Built by people who understand trials, and constrained to moving one step at a time while the need grows exponentially.

AI × Expert. AI removes what drains us. Humans amplify what matters. Human wisdom at tech-enabled velocity.

TIME ADOPTION TECHNOLOGY-LED EXPERT-LED AI × EXPERT

In 1976, Genentech’s founders set out to make human insulin in bacteria, something no one had done, rather than improve the animal insulin people had relied on since 1922. That is the kind of question I want us asking about trials.

Herbert Boyer and Robert Swanson at a chalkboard: E. coli, an arrow to a plasmid, plus synthetic DNA, and the plasmid carrying the new gene

In 1976,

Genentech’s founders set out to make human insulin in bacteria. No one had ever done it.

Look where we are today.

That is the kind of question I want us asking about trials.

Herb Boyer and Bob Swanson, 1976.

The answer is there. Reaching it is too slow.

Trials lose time to slow communication. When one person in a trial needs an answer from another, the question travels from inbox to inbox.

The sponsor is the company that pays for and runs a study, the site is the hospital or clinic where patients are seen, and the CRO is the contract research organization a sponsor hires to manage the work.

Friday, 6 PM. A coordinator at a clinical site has a patient on the phone, and a question:

A patient on the study drug has had diarrhea 6 times today. Her usual is 1. Is that Grade 2 or Grade 3 under the protocol? And does she take tonight’s dose?

Grade is how severe an event is, from 1 to 5. In this study, Grade 2 means keep dosing. Grade 3 means stop.

The coordinator emails the CRO. 2 hours later, the CRO passes it to the sponsor.

No answer by 9 PM. The investigator holds tonight’s dose to be safe, and the site asks again.

The sponsor reads it Saturday morning and asks its medical monitor, the physician a sponsor keeps on call for questions like this.

The medical monitor replies Monday at 8 AM. The answer reaches the coordinator at 9 AM:

63 hours and 3 missed doses, for one question.

Every piece of that answer already exists. Give the coordinator the sponsor’s protocol, the study’s own data and an FAQ to ask directly, and it comes back while the patient is on the line.

November 2026Fri to Mon
6 AM12 PM6 PM
Fri 6Site asks CROSite → CROCRO asks sponsorCRO → sponsorSite asks againSite asks again
Sat 7Sponsor asks medical monitorSponsor → medical monitor
Sun 8
Mon 9Medical monitor repliesMedical monitor repliesSponsor replies to siteSponsor → site
Patient callsCoordinator asksAnswer, with sourcesInvestigator confirms
ReplyReply AllForward
SC
Site Coordinator!URGENT: Grade 2 or 3? Dose due tonightTo CRO Monitor
CM
CRO MonitorFW: URGENT: Grade 2 or 3? Dose due tonightTo Sponsor Study Team Cc Site Coordinator
SC
Site CoordinatorRE: URGENT, 2nd request: Grade 2 or 3?To CRO Monitor
ST
Sponsor Study TeamFW: URGENT: Grade 2 or 3? Dose due tonightTo Medical Monitor Cc CRO Monitor
MM
Medical MonitorRE: FW: URGENT: Grade 2 or 3? Dose due tonightTo Sponsor Study Team
ST
Sponsor Study TeamFW: RE: FW: URGENT: Grade 2 or 3? Dose due tonightTo Site Coordinator Cc CRO Monitor

From: Site Coordinator
Sent: Friday, November 6, 2026 6:04 PM
To: CRO Monitor
Subject: URGENT: Grade 2 or 3? Dose due tonight

Patient on the phone. Diarrhea 6 times today, usual is 1. Not hospitalized. Investigator wants to confirm: Grade 2 or Grade 3 under the protocol? Dose is due at 9 PM.

Site Coordinator
Clinical Research Coordinator | Site 014 | Tel 555-0114

This email and any attachments are confidential and intended solely for the addressee. If you have received it in error, please notify the sender and delete it.

From: CRO Monitor
Sent: Friday, November 6, 2026 8:11 PM
To: Sponsor Study Team
Cc: Site Coordinator
Subject: FW: URGENT: Grade 2 or 3? Dose due tonight

Medical question. Passing this to the sponsor.

CRO Monitor
Clinical Research Associate | Study ABC-301 | Tel 555-0301

This email and any attachments are confidential and intended solely for the addressee. If you have received it in error, please notify the sender and delete it.

From: Site Coordinator
Sent: Friday, November 6, 2026 9:15 PM
To: CRO Monitor
Subject: RE: URGENT, 2nd request: Grade 2 or 3?

No answer yet. Investigator is holding tonight’s dose to be safe. Please advise.

Site Coordinator
Clinical Research Coordinator | Site 014 | Tel 555-0114

This email and any attachments are confidential and intended solely for the addressee. If you have received it in error, please notify the sender and delete it.

From: Sponsor Study Team
Sent: Saturday, November 7, 2026 10:23 AM
To: Medical Monitor
Cc: CRO Monitor
Subject: FW: URGENT: Grade 2 or 3? Dose due tonight

Can you advise on the grade?

Sponsor Study Team
Clinical Trial Manager | Study ABC-301 | Tel 555-0209

This email and any attachments are confidential and intended solely for the addressee. If you have received it in error, please notify the sender and delete it.

From: Medical Monitor
Sent: Monday, November 9, 2026 8:02 AM
To: Sponsor Study Team
Subject: RE: FW: URGENT: Grade 2 or 3? Dose due tonight

5 more than usual is Grade 2 under Table 7. No hold needed. Resume dosing.

Medical Monitor
Study Physician | Study ABC-301

This email and any attachments are confidential and intended solely for the addressee. If you have received it in error, please notify the sender and delete it.

From: Sponsor Study Team
Sent: Monday, November 9, 2026 9:04 AM
To: Site Coordinator
Cc: CRO Monitor
Subject: FW: RE: FW: URGENT: Grade 2 or 3? Dose due tonight

Grade 2. Resume dosing.

Sponsor Study Team
Clinical Trial Manager | Study ABC-301 | Tel 555-0209

This email and any attachments are confidential and intended solely for the addressee. If you have received it in error, please notify the sender and delete it.

All folders are up to date.Connected
Study portal · ask a question

ProtocolTable 7: 4 to 6 more a day than usual is Grade 2.
Study dataSimilar events here: Grade 2, dosing continued.
FAQGrade 2: keep dosing. Hold at Grade 3.
Answer ·

5 more than usual is Grade 2. The protocol says keep dosing.

Sources: protocol, study data, FAQ
The investigator confirms the grade, and the patient takes tonight’s dose.

63 hours to instantaneous response.

63 hours to instantaneous response.

When a case truly is new, it still goes to the medical monitor, with everything they need to answer it that evening.

That weekend is ordinary. Here is what a day looks like for the people who run a trial at a sponsor.

One Tuesday for a clinical trial manager at a sponsor. Every half hour is booked.

These are actually meetings and calls guised as operations.

More than half

of this day is communication: emails, calls, meetings and follow-ups.

Now make the routine communication asynchronous: written updates, read when there is time.

2.5 hours

open on this Tuesday. Communication still takes 3.5 hours.

Assumption: 8 of the 10 blocks become written updates at half their length. The medical monitor and safety calls stay live.

The clinical trial of tomorrow must be seamless, synergistic and synchronized.

02Seamless

Seamless. Meet them where they are.

Today, the patient travels to the site.

Adaptive and decentralized designs, so the trial travels to the patient instead of the patient traveling to the trial.

Seamless means meeting patients where they are.

03Synergistic

Synergistic. Sponsors, sites and CROs as partners.

Synchronized. One set of facts, available to everyone.

Today, work passes down a chain, one organization at a time.

The same people, in the same room, with the same incentive, rather than three organizations managing each other.

Today, each organization keeps its own copy of the facts.

Day 26 of a 28-day screening window. One question is left: does her adjuvant chemo count as a prior line of therapy? The coordinator asks the CRA, the CRA asks the CRO’s medical monitor, who asks the sponsor. The answer arrives on day 31, and she rescreens.

That same Saturday, another patient is admitted overnight. The serious event form goes in within 24 hours. The causality question comes back Monday, the investigator answers Tuesday, the sponsor’s physician reads the case Wednesday. Both answers were already in someone’s files.

Asynchronously synchronized: sponsor, CRO and site working from the same information at the same moment, without waiting on each other.

In the AI age this matters more. A model fed two records that disagree will answer confidently from either one. It needs one source of truth: readable data, good metadata, sources you can trace.

The data already exists. Why is it not accessible now?

Investigator Site File, Site 014ISF viewer
  • Tab 1  Delegation log
  • Tab 2  Protocol_v3.0_signature_page.pdf
  • Tab 5  IRB_approval_amendment3.pdf
  • Tab 6  ICF_v3_stamped.pdf
  • Tab 9  Training_log_Oct.xlsx
RECEIVED, not yet approved
  • Protocolv3.0
  • Ethics approvalpending
  • Retrained2 of 6
  • Consent formv3 in use
Site_status_tracker_v12_FINAL.xlsxSpreadsheet
ABCDEFGH
12013Dr. RuizActivev4.0approvedcompletev4 in useOct 14
13
14014Dr. OkaforActivev4.0submittednot updatedv4 sentOct 30
15015Dr. ChenActivev4.0approvedcompletev4 in useOct 21
16016Dr. PatelPendingv3.0pendingv3 in use
Site statusSheet2Sheet2 (copy)
Trial Master File, Study ABC-301eTMF
  • 01 Trial Management
  • 02 Central Trial Documents
    • Protocol_v4.0_final.pdf
    • ICF_v4_master.pdf
  • 03 Regulatory
  • 04 IRB or IEC and Other Approvals
    • Submission_amd3.pdf
  • 05 Site Management
    • Training_plan_v2.pdf
  • 06 IP and Trial Supplies

Protocol_v4.0_final.pdf

StatusFinal

Version4.0

Ethics approvalapproved

Site trainingcomplete

Consent formv4 in use

One source of truth

  • Protocol v4.0 issued. This site is on v3.0.Protocol_v4.0_final.pdf
  • Ethics approval: pending at this site.IRB_submission_amendment3.pdf
  • Site team retrained: 2 of 6.Training_log_Oct.xlsx
  • New consent form: not yet in use.ICF_v4_master.pdf
SponsorCROSite
04Synchronized
Seamless means

Meeting patients where they are, reducing patient burden instead of increasing it at a time when they already have too much going on.

Synergistic means

Sponsors, sites and CROs as partners: the same people, in the same room, with the same incentive, rather than three organizations managing each other.

Synchronized means

One set of facts, available to everyone: sponsor, CRO and site working from the same information at the same moment, without waiting on each other.

SeamlessMeet them where they are.
SynergisticSponsors, sites and CROs as partners.
SynchronizedOne set of facts, available to everyone.

Put those three together and everyone speaks the same language, with far less paper to carry it.

Together, they lead to a trial that is sustainable.

Sustainable means

Less burden.

Lower carbon.

Stronger science.

05Sustainable

“Novo Nordisk’s former chief scientific officer once noted that the documentation required to request approval for two insulin products, if printed and stacked, would rise higher than the Empire State Building.”

At a tenth of a millimeter a sheet, that is roughly 3.8 million pages.

Heights to scale.

Most of it does not have to exist.

AI and new ways of working can take the printing, filing and re-keying out of a trial.

Quote: Ruxandra Teslo, The New York Times Opinion, September 4, 2026. Page counts are arithmetic at 0.1 mm a sheet. Heights: Empire State Building 381 m to the roof, 443 m to the tip; Statue of Liberty 93 m, ground to torch; giraffe 5.5 m; person 1.75 m.

Where the weight comes off

One completed Phase 3 heart failure trial, measured from start to finish, came to 2,498

metric tons of carbon dioxide equivalent

The same as 582 gasoline cars driven for a year, or one car driven 10 million km.

Paper

Every page in that stack was printed, shipped, signed, filed and stored.

Electronic consent, electronic trial master files and electronic submissions take most of those steps away.

Documentation and communication came to 64 metric tons in that trial.

Travel

On-site monitoring means flights, hotel nights and rental cars for every visit.

A long drive for a short visit adds up over a study.

Remote and risk-based monitoring and visits at home, at a local clinic or by video keep those trips off the calendar and those kilometers off the road.

Site monitor visits were the largest line in that trial, 519 metric tons, mostly by car. Patient visits added 143.

Meetings

Investigator meetings, monitor meetings and committee meetings put people on flights to hospitals, clinics and conference rooms.

Most of those can happen by video, and nobody has to travel.

In-person trial meetings came to 404 metric tons in that trial.

Shipping

Frozen samples fly from every site to a central lab.

Regional labs shorten the trip.

Study drug, samples and test kits came to 752 metric tons in that trial, mostly freight. A significant share of that supply is never used.

Old against future

Take those lines down and the column looks like this.

About 60% less carbon, if every one of those lines moved.

From 582 cars on the road for a year to 582.

Hypothetical: published cuts applied to one measured trial.

Sources: Mackillop et al., “Carbon footprint of industry-sponsored late-stage clinical trials,” BMJ Open, 2023, Table 2 (the DAPA-HF trial). Future: Kohl and Schmidt-Lucke, PLOS Digital Health, 2023 (90.1%); Tao et al., Nature Communications, 2021 (94%, conferences); Subaiya et al., Trials, 2011 (60%, freight). US EPA Greenhouse Gas Equivalencies Calculator, 4.29 metric tons CO₂e per gasoline car per year (2,498 / 4.29 = 582; 1,012 / 4.29 = 236).

“We’ll find a way. We always have.”

Cooper, Interstellar (2014)

Medicine is helping us live longer.

Source: Mackillop et al., “Carbon footprint of industry-sponsored late-stage clinical trials,” BMJ Open, 2023. Clip: Interstellar (2014).

06In closing

What a resilient clinical trial looks like

Now, how many of you would participate in a trial that is…

…quick to adaptThe clock. Each wave of technology leaves less time to adapt than the one before.
…answered in minutesSlow communication. The answer is there. Reaching it is too slow.
…light on paperThe paper. Most of a stack as high as the Empire State Building does not have to exist.
…seamless, synergistic and synchronized

I know I would take part in this trial.

Would you?

“I believe that man will not merely endure:he will prevail.”

William Faulkner, 1954

William Faulkner, Nobel banquet speech, 1950

Next: Part 2

That’s how to run resilient clinical trials for resilient human beings. Part 2 covers the future of clinical trials and the hopeful future of where they will go in the next decade.

Read Part 2

Back to Ideas

Start a conversation.